In this study, we constructed a PBPK model of SGLT2 inhibitors, combined with a mathematical model of UGE, to simulate and predict changes in the PK and PD of SGLT2 inhibitors in healthy subjects and patients with T2DM and renal insufficiency. The gene discussed is SLC5A2; the disease is Renal insufficiency.